Effect of cold atmospheric plasma treatment on the metabolites of human leukemia cells.
Acute myeloid leukemia
Alanine, aspartate and glutamate metabolism
Cold atmospheric plasma
Metabolite profiling
d-Glutamine and d-glutamate metabolism
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
07
2018
accepted:
13
05
2019
entrez:
28
5
2019
pubmed:
28
5
2019
medline:
28
5
2019
Statut:
epublish
Résumé
Acute myeloid leukemia (AML) is a typically fatal malignancy and new drug and treatment need to be developed for a better survival outcome. Cold atmospheric plasma (CAP) is a novel technology, which has been widely applied in biomedicine, especially in various of cancer treatment. However, the changes in cell metabolism after CAP treatment of leukemia cells have been rarely studied. In this study, we investigated the metabolite profiling of plasma treatment on leukemia cells based on Gas Chromatography Tandem Time-of-Flight Mass Spectrometry (GC-TOFMS). Simultaneously, we conducted a series of bioinformatics analysis of metabolites and metabolic pathways with significant differences after basic data analysis. 800 signals were detected by GC-TOF mass-spectrometry and then evaluated using PCA and OPLS-DA. All the differential metabolites were listed and the related metabolic pathways were analyzed by KEGG pathway. The results showed that alanine, aspartate and glutamate metabolism had a significant change after plasma treatment. Meanwhile, d-glutamine and d-glutamate metabolism were significantly changed by CAP. Glutaminase activity was decreased after plasma treatment, which might lead to glutamine accumulation and leukemia cells death. We found the above two metabolic pathways vulnerable to plasma treatment, which might result in leukemia cells death and might be the cornerstone of further exploration of plasma treatment targets.
Sections du résumé
BACKGROUND
BACKGROUND
Acute myeloid leukemia (AML) is a typically fatal malignancy and new drug and treatment need to be developed for a better survival outcome. Cold atmospheric plasma (CAP) is a novel technology, which has been widely applied in biomedicine, especially in various of cancer treatment. However, the changes in cell metabolism after CAP treatment of leukemia cells have been rarely studied.
METHODS
METHODS
In this study, we investigated the metabolite profiling of plasma treatment on leukemia cells based on Gas Chromatography Tandem Time-of-Flight Mass Spectrometry (GC-TOFMS). Simultaneously, we conducted a series of bioinformatics analysis of metabolites and metabolic pathways with significant differences after basic data analysis.
RESULTS
RESULTS
800 signals were detected by GC-TOF mass-spectrometry and then evaluated using PCA and OPLS-DA. All the differential metabolites were listed and the related metabolic pathways were analyzed by KEGG pathway. The results showed that alanine, aspartate and glutamate metabolism had a significant change after plasma treatment. Meanwhile, d-glutamine and d-glutamate metabolism were significantly changed by CAP. Glutaminase activity was decreased after plasma treatment, which might lead to glutamine accumulation and leukemia cells death.
CONCLUSIONS
CONCLUSIONS
We found the above two metabolic pathways vulnerable to plasma treatment, which might result in leukemia cells death and might be the cornerstone of further exploration of plasma treatment targets.
Identifiants
pubmed: 31130824
doi: 10.1186/s12935-019-0856-4
pii: 856
pmc: PMC6525389
doi:
Types de publication
Journal Article
Langues
eng
Pagination
135Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Blood. 1977 Apr;49(4):511-33
pubmed: 14751
Nat Rev Cancer. 2004 Jul;4(7):551-61
pubmed: 15229480
Cell Metab. 2008 Jan;7(1):11-20
pubmed: 18177721
Genes Dev. 2009 Mar 1;23(5):537-48
pubmed: 19270154
Anal Chem. 2009 Dec 15;81(24):10038-48
pubmed: 19928838
Genome Res. 2010 May;20(5):589-99
pubmed: 20439436
Blood. 2010 Oct 21;116(16):3023-32
pubmed: 20664053
Br J Cancer. 2011 Oct 25;105(9):1295-301
pubmed: 21979421
Cancer Cell. 2012 Mar 20;21(3):297-308
pubmed: 22439925
Sci Rep. 2012;2:636
pubmed: 22957140
PLoS One. 2013 May 21;8(5):e64498
pubmed: 23704990
Biotechnol Bioeng. 2014 Mar;111(3):565-74
pubmed: 24022746
J Biol Chem. 2013 Nov 22;288(47):33542-58
pubmed: 24089526
Chem Biol. 2014 May 22;21(5):619-27
pubmed: 24746562
Int J Mol Med. 2014 Oct;34(4):941-6
pubmed: 25050490
J Cancer Prev. 2013 Sep;18(3):221-6
pubmed: 25337549
PLoS One. 2015 Jun 05;10(6):e0128205
pubmed: 26046915
PLoS One. 2015 Jun 17;10(6):e0126313
pubmed: 26083405
Wound Repair Regen. 2015 Nov-Dec;23(6):878-84
pubmed: 26342154
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Sci Rep. 2015 Dec 17;5:18339
pubmed: 26677750
Nat Rev Cancer. 2016 Oct;16(10):619-34
pubmed: 27492215
Oncotarget. 2016 Nov 29;7(48):79722-79735
pubmed: 27806325
J Cancer Prev. 2016 Dec;21(4):209-215
pubmed: 28053954
Free Radic Biol Med. 2018 Feb 1;115:43-56
pubmed: 29138018
Biomol Ther (Seoul). 2018 Jan 1;26(1):19-28
pubmed: 29212303